TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11693896

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg) via 15‐minute intravenous infusion
Number of subjects: 1648

Group type: COMPARATOR
Intervention: Pamidronate (90 mg) via 2‐hour intravenous infusion
Number of subjects: 1648

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg) and pamidronate
Number of subjects: 1648

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg)
Number of subjects: 1648

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 1648
Study: 30802201

Group type: COMPARATOR
Intervention: Test formulation (new tablet)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Reference formulation (original capsule)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both formulations under fed condition
Number of subjects: 40
Study: 28351544

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 38
Study: 24589044

Group type: EXPERIMENTAL
Intervention: Octenidine wound gel plus modern wound-phase-adapted dressings (treatment arm 2)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Octenidine wound gel alone (treatment arm 3)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Modern wound-phase-adapted dressings alone (treatment arm 1)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Octenidine wound gel treatment (treatment arms 2 and 3)
Number of subjects: 49
Study: 24184063

Group type: EXPERIMENTAL
Intervention: Contingent electrical stimulation (CES)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Inactive device (control group)
Number of subjects: 15
Study: 22820596

Group type: EXPERIMENTAL
Intervention: Painless urethral catheter placement combined with bladder washing with lidocaine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine catheter placement only
Number of subjects: 120
Study: 20798027

Group type: EXPERIMENTAL
Intervention: Workplace intervention (n=73)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Usual care (n=72)
Number of subjects: 145
Study: 17367349

Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Pre-filtered P-wave duration (FPD) >150 ms
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 3D electroanatomic mapping (3D-EAM)
Number of subjects: 51
Study: 16080809

Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ combination tablets (COAPROVEL)
Number of subjects: 920
Study: 12413243

Group type: EXPERIMENTAL
Intervention: Experimental treatment 1 (riluzole, dosage not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental treatment 2 (riluzole, dosage not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 10543927

Group type: EXPERIMENTAL
Intervention: 3 months supervised outpatient group training programme, 50 min three times a week (n=29)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (n=36)
Number of subjects: 65
Study: 8552456

Group type: EXPERIMENTAL
Intervention: Amodal completion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-forced-choice paradigm without feedback
Number of subjects: 0
Study: 2333674

Group type: EXPERIMENTAL
Intervention: Ioversol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 80
Study: 380872

Group type: EXPERIMENTAL
Intervention: 1% hydrocortisone cream
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 0.05% clobetasone butyrate (Eumovate)
Number of subjects: 54
Study: 31488427

Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Topical medication
Number of subjects: 167
Study: 31852499

Group type: EXPERIMENTAL
Intervention: Mass drug administration for malaria transmission interruption
Number of subjects: 0
Study: 27762570

Group type: EXPERIMENTAL
Intervention: Threat of accusation of misconduct (Experiment 1)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Self-regulatory decline during questioning (Experiment 2)
Number of subjects: 476
Study: 25858494

Group type: EXPERIMENTAL
Intervention: Inorganic nitrate (NO3 (‐)) supplementation via beetroot juice (8.4 mmol NO3 (‐)/day)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 7
Study: 23357841

Group type: EXPERIMENTAL
Intervention: 25 mg sirukumab
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 50 mg sirukumab
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 100 mg sirukumab
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 21258039

Group type: EXPERIMENTAL
Intervention: Emulsion combining glycerol and paraffin applied twice daily for 7 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Emulsion alone (comparator) applied twice daily for 7 days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Emulsion combining glycerol and paraffin
Number of subjects: 100
Study: 19549643

Group type: EXPERIMENTAL
Intervention: General anaesthesia PCA with opioids (fentanyl 6 microg ml(‐1) and tramadol 3 mg ml(‐1))
Number of subjects: 48

Group type: COMPARATOR
Intervention: Combined general/epidural anaesthesia plus patient‐controlled epidural analgesia (PCEA)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: General anaesthesia PCA with opioids (fentanyl and tramadol)
Number of subjects: 48
Study: 17578937

Group type: EXPERIMENTAL
Intervention: Monophasic pulsed current (PC) with a frequency of 50 Hz and a phase duration of 500 microseconds
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Burst-modulated alternating current (BMAC) (1-kHz alternating current, burst modulated at a frequency of 50 Hz with a 20% duty cycle)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Comparison of PC and BMAC
Number of subjects: 19
Study: 15631774

Group type: EXPERIMENTAL
Intervention: Neurotropin (6 ml, IV, QD for 2 weeks, then 2 tablets, BID for another 2 weeks)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Methycobal (1 ml, IM, QD for 2 weeks, then 1 tablet TID for another 2 weeks)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Neurotropin
Number of subjects: 95

Group type: COMPARATOR
Intervention: Methycobal
Number of subjects: 95
Study: 11494088

Group type: EXPERIMENTAL
Intervention: Right arm blood pressure measurement
Number of subjects: 237

Group type: COMPARATOR
Intervention: Left arm blood pressure measurement
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Inter-arm difference of 10 mm Hg or greater for diastolic blood pressure
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Inter-arm difference of 20 mm Hg or more for systolic blood pressure
Number of subjects: 237
Study: 9210750

Group type: EXPERIMENTAL
Intervention: 0.75 ml/kg of alcohol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8135469

Group type: EXPERIMENTAL
Intervention: 500 mg Aminoglutethimide (AG) daily
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: 1000 mg Aminoglutethimide (AG) daily
Number of subjects: 106

Group type: COMPARATOR
Intervention: Cortisone Acetate (CA) replacement dose 37.5 mg/day orally (used in both groups)
Number of subjects: 106
Study: 3479419

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin 750 mg bid
Number of subjects: 18

Group type: COMPARATOR
Intervention: Oral ofloxacin 400 mg bid
Number of subjects: 18
Study: 31077229

Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unattended automated blood pressure monitoring (uAOBP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Central BP-guided treatment
Number of subjects: 0
Study: 29231429

Group type: EXPERIMENTAL
Intervention: Manual Acupuncture
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 50
Study: 25458463

Group type: EXPERIMENTAL
Intervention: Inhaled glutathione (GSH)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 23785463

Group type: EXPERIMENTAL
Intervention: Streptococcus salivarius M18 (various doses)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Streptococcus salivarius M18
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Megaplasmid transfer to S. salivarius
Number of subjects: 75
Study: 21961534

Group type: EXPERIMENTAL
Intervention: Exercise group (EG, n = 52) - supervised aerobic dance and strength training for 60 minutes, twice per week for a minimum of 12 weeks
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (CG, n = 53)
Number of subjects: 105
Study: 19100344

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) for 3 months
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 40
Study: 16502768

Group type: EXPERIMENTAL
Intervention: EZE/SIMVA 10/10 mg/mg
Number of subjects: 96

Group type: COMPARATOR
Intervention: EZE 10 mg + SIMVA 10 mg
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: EZE/SIMVA 10/80 mg/mg
Number of subjects: 96

Group type: COMPARATOR
Intervention: EZE 10 mg + SIMVA 80 mg
Number of subjects: 96
Study: 15337642

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy for suicidal behavior
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative study designs (add-on trials)
Number of subjects: 0
Study: 10551700

Group type: EXPERIMENTAL
Intervention: Clinical and angiographic follow-up (AF)
Number of subjects: 706

Group type: COMPARATOR
Intervention: Clinical follow-up (CF)
Number of subjects: 706
Study: 8682733

Group type: EXPERIMENTAL
Intervention: DRO schedule with high-preference stimuli associated with high rates of SIB (HP/HS)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: DRO schedule with low-preference stimuli associated with low rates of SIB (LP/LS)
Number of subjects: 2
Study: 1998637

Group type: EXPERIMENTAL
Intervention: External cephalic version (ECV) attempted after intravenous injection of 10 micrograms of hexaprenaline.
Number of subjects: 208

Group type: COMPARATOR
Intervention: Control group (no intervention mentioned).
Number of subjects: 208
Study: 6677076

Group type: EXPERIMENTAL
Intervention: Disulfiram (250 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Visual ratings
Number of subjects: 14
Study: 31016337

Group type: EXPERIMENTAL
Intervention: Stabilization exercise (SE)
Number of subjects: 68

Group type: COMPARATOR
Intervention: General exercise (GE)
Number of subjects: 68
Study: 31482956

Group type: EXPERIMENTAL
Intervention: Hemoglobin (Hb) levels
Number of subjects: 49296

Group type: EXPERIMENTAL
Intervention: Hemoglobin (Hb) levels in women
Number of subjects: 49296

Group type: EXPERIMENTAL
Intervention: Hemoglobin (Hb) levels in men
Number of subjects: 49296
Study: 28121991

Group type: EXPERIMENTAL
Intervention: Anode Right/Cathode Left (AR/CL) tDCS
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Anode Left/Cathode Right (AL/CR) tDCS
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: AR/CL tDCS
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: AL/CR tDCS
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: All tDCS sessions
Number of subjects: 39
Study: 25886901

Group type: EXPERIMENTAL
Intervention: Dexamethasone 1 mg/kg
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study: 23080334

Group type: EXPERIMENTAL
Intervention: Basilic vein transposition (BVT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Arteriovenous access grafts (AVG)
Number of subjects: 60
Study: 21121925

Group type: EXPERIMENTAL
Intervention: Parent-training program (PT)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 186
Study: 19682376

Group type: EXPERIMENTAL
Intervention: NP 06‐1 (Phellodendron amurense bark and Citrus sinensis peel) 740 mg/day (two capsules of 370 mg each, twice daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 17258690

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 407

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 407
Study: 15307856

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily
Number of subjects: 5241

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg once daily
Number of subjects: 5241
Study: 12385434

Group type: EXPERIMENTAL
Intervention: Combination of omeprazole, amoxicillin, and clarithromycin for 1 week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched placebo for 1 week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized absorbance change
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10% decline in standardized absorbance after 1 year
Number of subjects: 0
Study: 10627977

Group type: EXPERIMENTAL
Intervention: Minimally invasive coronary bypass (last two periods)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sternotomy on a beating heart (n=12, 62.6 ± 8.2)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sternotomy under CPB (n=81, 63.0 ± 8.5)
Number of subjects: 27
Study: 7593503

Group type: EXPERIMENTAL
Intervention: Follicle stimulating hormone (FSH)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Human menopausal gonadotrophin (HMG)
Number of subjects: 232
Study: 2256497

Group type: EXPERIMENTAL
Intervention: Pulsed oxytocin (every 8 minutes)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Continuous oxytocin (intravenous infusion)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 106
Study: 7001489

Group type: EXPERIMENTAL
Intervention: Frusemide 40 mg twice daily
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Frusemide 60 mg twice daily
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Frusemide 80 mg twice daily
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Frusemide (all dosages)
Number of subjects: 26
Study: 6406090

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 10
Study: 29194182

Group type: EXPERIMENTAL
Intervention: Kicking with elastic resistance during warm-up
Number of subjects: 16
Study: 26296610

Group type: EXPERIMENTAL
Intervention: 5-day high-fat overfeeding (HFO) (60 E% fat, +50% calories)
Number of subjects: 44
Study: 24768938

Group type: EXPERIMENTAL
Intervention: Direct assignment design with two interim analyses (DAD-2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Balanced randomized design with two interim analyses (BRD-2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Direct assignment design with one interim analysis (DAD-1)
Number of subjects: 0
Study: 22624284

Group type: EXPERIMENTAL
Intervention: RoboLeader (intelligent agent) perfectly reliable
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RoboLeader (intelligent agent) false-alarm prone (60% reliability)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RoboLeader (intelligent agent) miss prone (60% reliability)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RoboLeader (intelligent agent) false-alarm prone (90% reliability)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RoboLeader (intelligent agent) miss prone (90% reliability)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual density manipulation (presence or absence of friendly soldiers)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual differences (attentional control and video gaming experience)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spatial ability
Number of subjects: 0
Study: 20668448

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 18613319

Group type: EXPERIMENTAL
Intervention: Decision aid
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control pamphlet
Number of subjects: 148
Study: 16061831

Group type: EXPERIMENTAL
Intervention: PEG-GHRH (0.25, 0.5, 2 or 4 mg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: PEG-GHRH
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 12695732

Group type: EXPERIMENTAL
Intervention: Soteria treatment (minimal use of antipsychotic medication)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Usual hospital treatment (control)
Number of subjects: 179
Study: 10486417

Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 1518

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1518
Study: 7492836

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 1835731

Group type: EXPERIMENTAL
Intervention: alpha-interferon (alpha-IFN) at least 5 MU/m2 t.i.w. for a minimum of 3 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: alpha-interferon (alpha-IFN) at a standard dose of 5 MU QD or 9 MU t.i.w. for at least 1 year
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: alpha-interferon (alpha-IFN) therapy
Number of subjects: 0
Study: 7044880

Group type: EXPERIMENTAL
Intervention: 15(R)-15-methyl prostaglandin E2 (arbaprostil) 100 microgram capsules, taken four times a day for 28 days
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo capsules, taken four times a day for 28 days
Number of subjects: 173
Study: 31260752

Group type: EXPERIMENTAL
Intervention: Linguistic summarization system using algorithms to extract health-related features from sensor data.
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Linguistic summarization system producing summaries of data leading to health alerts.
Number of subjects: 110
Study: 29098261

Group type: EXPERIMENTAL
Intervention: Micro-implant anchorage
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional anchorage
Number of subjects: 20
Study: 26207431

Group type: EXPERIMENTAL
Intervention: PCEA: Combined spinal-epidural anesthesia (CSE) with a PCEA of ropivacaine 0.1% + sufentanil 0.5 μg/mL for 24 hours after CS
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: ED: CSE with an ED bolus of 3 mg morphine after CS
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: IT: spinal anesthesia with an IT bolus of 0.1 mg morphine before CS
Number of subjects: 199
Study: 24418597

Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation intervention (tailored counselling during face-to-face visits, weekly for the first four weeks, monthly to six months, and two monthly to 12 months)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Usual care (routine care relating to smoking cessation at local primary health care service)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation intervention (compared to usual care)
Number of subjects: 163
Study: 22133450

Group type: EXPERIMENTAL
Intervention: Online Chronic Pain Management Program (self-directed, self-paced, 6 weeks)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Wait-listed control group (treatment as usual)
Number of subjects: 162
Study: 19648310

Group type: EXPERIMENTAL
Intervention: Topical 1% diclofenac sodium gel (Voltaren Gel)
Number of subjects: 385

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 385
Study: 17450706

Group type: EXPERIMENTAL
Intervention: Tailored education
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Targeted education
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Tailored education with booster messages
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Targeted education with booster messages
Number of subjects: 343
Study: 15228193

Group type: EXPERIMENTAL
Intervention: 844ins68 allele in the cystathionine beta-synthase gene
Number of subjects: 1087

Group type: EXPERIMENTAL
Intervention: Heterogeneity among Jewish communities
Number of subjects: 1087

Group type: EXPERIMENTAL
Intervention: Distribution of 844ins68 allele
Number of subjects: 1087

Group type: EXPERIMENTAL
Intervention: Use of 844ins68 as an anthropogenetic marker
Number of subjects: 1087
Study: 11452240

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (250 mL)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Red wine (cabernet sauvignon)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study: 9570605

Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine (30 mg initial bolus, 6 mL)
Number of subjects: 42

Group type: COMPARATOR
Intervention: 5% lidocaine (30 mg initial bolus, 0.6 mL)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine
Number of subjects: 42

Group type: COMPARATOR
Intervention: 5% lidocaine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study: 7923311

Group type: EXPERIMENTAL
Intervention: Intra-arterial antibiotic infusion therapy (Group A)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion therapy plus percutaneous drainage of the abscess (Group B)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Intravenous antibiotics alone (Group C)
Number of subjects: 14
Study: 3144165

Group type: EXPERIMENTAL
Intervention: Encainide (75 to 240 mg/day)
Number of subjects: 49
Study: 30791874

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Social Behaviour and Network Therapy
Number of subjects: 49
Study: 28809654

Group type: EXPERIMENTAL
Intervention: Family Caregiver Training Program (FCTP)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 36
Study: 25847793

Group type: EXPERIMENTAL
Intervention: Intralesional PPD
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intralesional MMR
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 30
Study: 23932181

Group type: COMPARATOR
Intervention: Hydroxyethyl starch (HES) alone
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) plus cabergoline (0.5mg for 8 days)
Number of subjects: 182
Study: 21233775

Group type: EXPERIMENTAL
Intervention: Soft-flat orthosis
Number of subjects: 20

Group type: COMPARATOR
Intervention: Contoured orthoses
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Walking
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Jogging
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Orthoses judged as comfortable as my shoe
Number of subjects: 20
Study: 19922128

Group type: EXPERIMENTAL
Intervention: 40 mg/day glatiramer acetate (GA)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 366
Study: 17144568

Group type: EXPERIMENTAL
Intervention: Fish/n-3 polyunsaturated fatty acids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing intake of fish/n-3 polyunsaturated fatty acids
Number of subjects: 0
Study: 15232656

Group type: EXPERIMENTAL
Intervention: 3D‐SSP presentation
Number of subjects: 72

Group type: COMPARATOR
Intervention: Transaxial section presentation
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 3D‐SSP
Number of subjects: 72